<figure><img src="image_1.png" /></figure>

Check for
updates

# Sub-MICs of Azithromycin Decrease Biofilm Formation of *Streptococcus suis* and Increase Capsular Polysaccharide Content of *S. suis*

Yan-Bei Yang<fnref n="1" />, Jian-Qing Chen<fnref n="1" />, Yu-Lin Zhao<fnref n="1" />, Jing-Wen Bai<fnref n="1" />, Wen-Ya Ding<fnref n="1" />, Yong-Hui Zhou<fnref n="1" />, Xue-Ying Chen<fnref n="1" />, Di Liu² and Yan-Hua Li<fnref n="1" />*

*Streptococcus suis* (S. *suis*) caused serious disease symptoms in humans and pigs. S. *suis* is able to form thick biofilms and this increases the difficulty of treatment. After growth with 1/2 minimal inhibitory concentration (MIC) of azithromycin, 1/4 MIC of azithromycin, or 1/8 MIC of azithromycin, biofilm formation of S. *suis* dose-dependently decreased in the present study. Furthermore, scanning electron microscopy analysis revealed the obvious effect of azithromycin against biofilm formation of S. *suis*. Especially, at two different conditions (1/2 MIC of azithromycin non-treated cells and treated cells), we carried out comparative proteomic analyses of cells by using iTRAQ technology. Finally, the results revealed the existence of 19 proteins of varying amounts. Interestingly, several cell surface proteins (such as ATP-binding cassette superfamily ATP-binding cassette transporter (G7SD52), CpsR (K0FG35), Cps1/2H (G8DTL7), CPS16F (E9NQ13), putative uncharacterized protein (G7SER0), NADP-dependent glyceraldehyde-3-phosphate dehydrogenase (G5L259), putative uncharacterized protein (G7S2D6), amino acid permease (B0M0G6), and NsuB (G5L351)) were found to be implicated in biofilm formation. More importantly, we also found that azithromycin affected expression of the genes *cps1/2H*, *cpsR* and *cps16F*. Especially, after growth with 1/2 MIC of azithromycin and 1/4 MIC of azithromycin, the capsular polysaccharide content of S. *suis* was significantly higher.

**Keywords:** proteomics, *Streptococcus suis*, azithromycin, biofilm formation, capsular polysaccharide

## OPEN ACCESS

**Edited by:**
Abelardo Margolles
Spanish National Research Council,
Spain

**Reviewed by:**
Vishvanath Tiwari,
Central University of Rajasthan, India
Zuowei Wu,
Iowa State University, USA

*Correspondence:
Yan-Hua Li
liyanhua1970@163.com

**Specialty section:**
This article was submitted to *Antimicrobials, Resistance and Chemotherapy*, a section of the journal *Frontiers in Microbiology*

**Received:** 21 June 2016
**Accepted:** 05 October 2016
**Published:** 20 October 2016

**Citation:**
Yang Y-B, Chen J-Q, Zhao Y-L, Bai J-W, Ding W-Y, Zhou Y-H, Chen X-Y, Liu D and Li Y-H (2016) *Sub-MICs of Azithromycin Decrease Biofilm Formation of Streptococcus suis and Increase Capsular Polysaccharide Content of S. suis*. *Front. Microbiol.* 7:1659.
doi: 10.3389/fmicb.2016.01659

## INTRODUCTION

*Streptococcus suis* (S. *suis*) causes serious disease symptoms. It is one of the most important pathogens, and it is responsible for pneumonia, arthritis, septicemia, and meningitis in pigs and humans (Bojarska et al., 2016). So far, some researchers have reported that S. *suis* is able to form biofilms (Wang et al., 2015; Bojarska et al., 2016; Espinosa et al., 2016). Biofilm structures are packaged along with proteins, nucleic acids, extracellular polysaccharides (EPS), and other materials. Microbial cells within biofilm structures are tolerant to the host immune system, heat treatment, and antibiotics (Nakamura et al., 2016).

In accordance with the antigenicity of the capsule, the S. *suis* serotypes are determined. capsular polysaccharide synthesis (CPS) genes are located at the cps locus. Production of the capsule is

<footnote n="1">¹ College of Veterinary Medicine, Northeast Agricultural University, Harbin, China, ² Heilongjiang Academy of Agricultural Sciences, Harbin, China</footnote>
encoded by CPS genes (Smith et al., 1999). Especially, previous studies have shown that the *S. suis* serotype 2 mutant impaired in capsule expression acquire a biofilm-positive phenotype (Tanabe et al., 2010). Moreover, a hydrophilic capsule may hinder hydrophobic structures or components important for biofilm formation by *S. suis* (Bonifait et al., 2010).

Azithromycin is an antibiotic useful for the treatment of bacterial infections. It is common knowledge that azithromycin is derived from erythromycin, belonging to macrolide. Recently, some reports have showed that subinhibitory concentrations of azithromycin decreases biofilm formation (Starner et al., 2008; Gui et al., 2014). Our laboratory recently reported that sub-minimal inhibitory concentrations (MICs) of tylosin and sub-MICs of erythromycin decreased biofilm formation of *S. suis* ATCC700794 (Zhao et al., 2015; Wang et al., 2016). However, the relationship between azithromycin and biofilm formation by *S. suis* remains poorly understood. Therefore, the purpose of this study was to describe the use of proteomics to better understand the impact of azithromycin on *S. suis* biofilms in vitro. We found that azithromycin affected the CPS enzymes. Several cell surface proteins [such as ATP-binding cassette (ABC) superfamily ATP-binding cassette transporter (G7SD52), CpsR (K0FG35), Cps1/2H (G8DTL7), CPS16F (E9NQ13), putative uncharacterized protein (G7SER0), NADP-dependent glyceraldehyde-3-phosphate dehydrogenase (G5L259), putative uncharacterized protein (G7S2D6), amino acid permease (B0M0G6), and NsuB (G5L351)] were found to be implicated in biofilm formation. Especially, after growth with 1/2 MIC of azithromycin and 1/4 MIC of azithromycin, the capsular polysaccharide (CP) content of *S. suis* was significantly higher.

# MATERIALS AND METHODS

## Bacterial Strains and Growth Conditions

*Streptococcus suis* ATCC700794 was used in this study. Bacteria were grown aerobically at 37°C in Todd-Hewitt broth (THB; Summus Ltd, Harbin, Heilongjiang, China) or Todd-Hewitt broth agar (THA) supplemented with 5% (v/v) fetal bovine serum (Sijiqing Ltd, Hangzhou, Zhejiang, China). The cultures were used for the biofilm assays and the MIC assays.

## Determination of Growth Inhibition Activity of Azithromycin

Minimal inhibitory concentration assays of azithromycin were done three times (refer to Yang et al., 2015), with a few modifications. Briefly, *S. suis* ATCC700794 was grown aerobically at 37°C in THB (Summus Ltd, Harbin, Heilongjiang, China) overnight. The overnight cultures were diluted in sterile physiological saline (corresponding to $1 \times 10^8$ colony-forming units/ml). Then, dilute the cultures of *S. suis* ATCC700794 1:100 using sterile THB (Summus Ltd, Harbin, Heilongjiang, China). Finally, samples ($100 \mu l$) were added to the wells of a 96-well plate (Corning Costar®3599, Corning, NY, USA) containing serial dilutions of azithromycin in culture medium. Control bacteria were cultivated in the absence of azithromycin. The MIC was determined as the lowest concentration of azithromycin that

completely inhibited *S. suis* growth after incubation for 24 h at 37°C.

The growth rates of *S. suis* ATCC700794 treated with 1/2 MIC of azithromycin and untreated *S. suis* ATCC700794 were analyzed (refer to Yang et al., 2015). Briefly, *S. suis* ATCC700794 treated without azithromycin and *S. suis* ATCC700794 treated with azithromycin (1/2 MIC) were incubated at 37°C for 12 h. Then, the samples were taken every hour for measuring OD 600 nm.

## Biofilm Assay

Overnight cultures of *S. suis* were diluted in sterile THB supplemented with 5% (v/v) fetal bovine serum (corresponding to $1 \times 10^8$ colony-forming units/ml). Then, the diluted overnight cultures ($200 \mu l$) was grown (24 h) in a 96-well plate (Corning Costar® 3599, Corning, NY, USA) in the presence of 1/2 MIC, 1/4 MIC, 1/8 MIC, or 1/16 MIC of azithromycin. *S. suis* ATCC700794 treated without azithromycin was served as a control. Biofilms were treated as described by Yang et al. (2015) with some modifications. Briefly, the medium, free-floating bacteria, and loosely bound biofilm were then removed by aspiration, and the wells were washed three times with sterile physiological saline. The remaining attached bacteria were fixed with $200 \mu l$ of 99% methanol (Guoyao Ltd, China) per well, and then the wells were left to dry. The wells were dyed for 30 min with $200 \mu l$ of 0.1% crystal violet (Sularbao Ltd, Beijing, China) per well. The stain was washed with water. Then, the dye was solubilized with $200 \mu l$ of 33% glacial acetic acid per well. Finally, the samples were measured the absorbance at 570 nm.

## Scanning Electron Microscopy

The biofilm structure of *S. suis* was observed by scanning electron microscopy (refer to Yang et al., 2015). Briefly, overnight cultures of *S. suis* were diluted in sterile THB supplemented with 5% (v/v) fetal bovine serum (corresponding to $1 \times 10^8$ colony-forming units/ml). Then, the diluted overnight cultures with 1/2 MIC of azithromycin or without azithromycin were added into wells of a six-well plate containing rough glass slide or glass slide. Free-floating bacteria and medium were removed after 24 h in culture. The biofilms were incubated overnight in fixation buffer, washed with cacodylate buffer and post-fixed for 90 min at room temperature in 1% (w/v) osmic acid containing 2 mM potassium ferrocyanide and 6% (w/v) sucrose in cacodylate buffer. Samples were dehydrated through a graded series of ethanol (50, 70, 95, and 100%), critical point dried, gold sputtered and examined using a scanning electron microscopy.

## iTRAQ Analysis

Protein was extracted from *S. suis* cells at two different conditions (1/2 MIC of azithromycin-treated cells and non-treated cells). iTRAQ analysis was implemented at Shanghai Applied Protein Technology Co. Ltd (APT, Shanghai, China). Three biological replicates were evaluated to minimize the influence of less reliable quantitative information. iTRAQ analyses were performed as described by Zhao et al. (2015). Briefly, protein digestion was performed according to the FASP procedure and the resulting peptide mixture was labeled using the 8-plex iTRAQ
reagent. iTRAQ-labeled peptides were fractionated by strong cation exchange (SCX) chromatography using the AKTA Purifier system. LC-MS/MS analysis was performed on a Q Exactive mass spectrometer that was coupled to Easy nLC (Proxeon Biosystems, now Thermo Fisher Scientific).

## Sequence Database Searching and Data Analysis

Sequence database searching and data analysis were implemented at Shanghai Applied Protein Technology Co. Ltd (APT, Shanghai, China). Briefly, MS/MS spectra were searched using MASCOT engine embedded into Proteome Discoverer 1.3 against Uniprot database (133549 sequences, download at March 3, 2013) and the decoy database. For protein identification, the following options were used. Peptide mass tolerance = 20 ppm, MS/MS tolerance = 0.1 Da, enzyme = Trypsin, missed cleavage = 2, fixed modification: Carbamidomethyl (C), iTRAQ8plex(K), iTRAQ8plex (N-term), and variable modification: oxidation (M), FDR ≤ 0.01.

## Quantitative RT-PCR Analysis

We investigated the effect of 1/2 MIC of azithromycin on the gene expression of CPS enzymes (CpsR, Cps1/2H, and CPS16F). *S. suis* was grown to mid-log phase and then the culture medium was supplemented with 1/2 MIC of azithromycin prior to further incubate at 37°C for 24 h. Control cells were incubated in the absence of azithromycin.

Quantitative RT-PCR were implemented as described by Yang et al. (2015).

Briefly, bacteria were collected by centrifugation (10,000 × g for 5 min) and treated with an RNASE REMOVER I (Huayueyang Ltd, Beijing, China). Total RNA was extracted with a Bacterial RNA isolating kit (Omega, Beijing, China) according to the manufacturer's protocol. RNA was reverse transcribed using Maloney murine leukemia virus reverse transcriptase and random hexamers in a S1000TM thermal cycler. Reverse transcription conditions were 90 min at 42°C and 15 min at 70°C. Real-time PCR was used for quantification of *cpsR*, *cps1/2H*, and *cps16F* mRNA expression. Relative copy numbers and expression ratios of selected genes were normalized to the expression of 16S rRNA gene (housekeeping gene). The 16S rRNA gene was used as an internal control for specific primers. The specific primers used for the quantitative RT-PCR were purchased from Takara and are listed in Table 1. Triplicate reactions were prepared with 25 µl of PCR mixture containing 12.5 µl of IQ SYBR Green Supermix, 5 µl of cDNA, 1 µl of gene-specific primer, and 6.5 µl of RNase- and DNase-free water. The samples were amplified using a Bio-Rad MyCycler™ thermal cycler (Bio-Rad Laboratories). The amplification conditions for *cpsR*, *cps1/2H*, *cps16F*, and 16S rRNA were 94°C for 10 min followed by 40 cycles at 94°C for 15 s, 60°C for 60 s.

## Quantitative Determination of CP

*Streptococcus suis* ATCC700794 was treated with 1/2 MIC, 1/4 MIC or 1/8 MIC of azithromycin. *S. suis* ATCC700794 treated without azithromycin was served as a control. Isolation and

<table><caption>TABLE 1 | Primers used for the quantitative RT-PCR analysis.</caption><thead><tr><th>Genes</th><th>Primer sequence</th></tr></thead><tbody><tr><td>cps1/2H</td><td>Forward: 5'-GCCTCTTATTCAGGTTAT-3'<br>Reverse: 5'-GTTCTGCTACTGTTTCTC-3'</td></tr><tr><td>cps16F</td><td>Forward: 5'-TGAACATAATGGAGCAAC-3'<br>Reverse: 5'-AGGACCAATCCGACAAGC-3'</td></tr><tr><td>cpsR</td><td>Forward: 5'-TTCGGTAGTAGAAGGTTCAAGAC-3'<br>Reverse: 5'-AACACGCAAAGCTAAATAGGTAT-3'</td></tr><tr><td>16S rRNA</td><td>Forward: 5'-GATATATGGAGGAACACCG-3'<br>Reverse: 5'-GACCCAACACCTAGCACT-3'</td></tr></tbody></table>

purification of the CP from *S. suis* ATCC700794 were performed as described by Yufang et al. (refer to Yufang et al., 2006). Briefly, a 10-ml overnight culture was used to inoculate 1L of THB containing 5% (v/v) fetal bovine serum for 24 h at 37°C. The bacterial cells were recovered by centrifugation and washed twice with PBS. The pellet was suspended in 100 ml of glycine buffer containing 100 mg lysozyme (Sigma). After incubation at 37°C for 8 h, the supernatant was recovered following centrifugation. The supernatant was treated with 20 mg of DNase (Sigma) and 10 mg of RNase (Sigma) at 37°C for 1 h. Proteinase K (20 mg) was added for 2 h at 55°C. The supernatant was brought to a concentration of 30% (v/v) ethanol and allowed to stand at 4°C for 2 h. The precipitate formed was removed by centrifugation, and the supernatant was brought to a concentration of 80% ethanol and allowed to stand at 4°C overnight. The precipitate was recovered by centrifugation and dried. Quantitative determination of the CP was performed as described by Cuesta et al. (2003). Briefly, the phenol solution (0.3 ml) and the CP solution (0.6 ml) were added to screw cap tubes, which were capped and vortex-stirred. Then 1.5 ml of concentrated sulfuric acid was added directly to the tube. The tubes were then closed, vortex-stirred for 5 s and incubated for 30 min. All samples were read the absorbances at 490 nm using distilled water as blank in a UV-7504 spectrophotometer (Jingke Ltd, Shanghai, China). Standard curve of glucose was performed as above described. The CP content was expressed according to the formula: CP content (%) = (C × D × F/W) × 100, where C is sugar concentration in the sample, D is dilution factor in the sample, F is conversion factor (3.19), and W is CP weight in the sample.

## Statistical Analysis

Assays were done three times and the means ± standard deviations were computed. Data were analyzed using the Student t-test.

## RESULTS

Minimal inhibitory concentration of azithromycin against *S. suis* ATCC700794 was 32 µg/ml in the present study. Furthermore, after 10 h incubation at 37°C, untreated *S. suis* ATCC 700794 and treated (1/2 MIC of azithromycin) *S. suis* ATCC 700794 reached stationary phase, indicating no effect on growth rate of *S. suis* ATCC700794 (Figure 1). After growth without
azithromycin (control) or with 1/2 MIC of azithromycin, 1/4 MIC of azithromycin, 1/8 MIC of azithromycin, or 1/16 MIC of azithromycin, biofilm formation of *S. suis* was investigated (Figure 2). When the culture medium was supplemented with 1/2 MIC of azithromycin, 1/4 MIC of azithromycin, or 1/8 MIC of azithromycin, the biofilms of *S. suis* were significantly lower in comparison with the control (*p* < 0.05). However, after growth with 1/16 MIC of azithromycin, the biofilms were not significantly affected (*p* > 0.05).

Scanning electron microscopy analysis was performed to observe the azithromycin sub-MIC-induced biofilm formation by *S. suis*. As shown in **Figures 3A,C** (control), a thick biofilm made of aggregates and microcolonies almost completely covered the surface of the glass slide. However, when the culture medium was supplemented with 1/2 MIC of azithromycin, individual short chains of *S. suis* and individual pairs of *S. suis* attached to the glass slide or rough glass slide (**Figures 3B,D**). Scanning electron microscopy analysis revealed that 1/2 MIC of azithromycin significantly decreased biofilm formation by *S. suis*.

iTRAQ technology was used to compare the patterns of protein expression at two different conditions (1/2 MIC of azithromycin treated cells and non-treated cells). When a protein had both a fold-change of more that a ratio >2.0 or <0.5 (*p*-value < 0.05), the protein was considered differentially expressed. On the basis of the two criteria, 19 differentially expressed proteins were identified, 12 (63.2%) of which displayed increased, and 7 (36.8%) displayed decreased abundance (**Table 2**). According to the molecular function, these proteins were classified into following categories: nucleotide binding (4, 21.1%), DNA binding (1, 5.3%), catalytic activity (7, 36.8%), RNA binding (1, 5.3%), protein binding (1, 5.3%), structural molecule activity (1, 5.3%), transporter activity (1, 5.3%), motor activity (1, 5.3%), and unknown molecular function (9, 47.4%). According

to the cellular component, these proteins were classified into following categories: membrane (9, 47.4%), cytoplasm (2, 10.5%), extracellular (1, 5.3%), cytoskeleton (1, 5.3%), and unknown cellular component (9, 47.4%). According to the biological process, these proteins were classified into following categories: metabolic process (5, 26.3%), cell organization and biogenesis (1, 5.3%), regulation of biological process (1, 5.3%), transport (2, 10.5%), cellular homeostasis (1, 5.3%), and unknown biological process (12, 63.2%). Detailed information can be found in Supplementary Table S1. The majority of the proteins were involved in catalytic activity (7, 36.8%) and metabolism (5, 26.3%). These findings suggested that 1/2 MIC of azithromycin-treated cells and non-treated cells were subjected to different pharmic selective pressures, which might result in different proteome patterns.

When the culture medium was supplemented with 1/2 MIC of azithromycin, expression of the genes *cps1/2H* was upregulated (*p* < 0.05; **Figure 4**). However, as shown in **Figure 4**, when the culture medium was supplemented with 1/2 MIC of azithromycin, expression of the genes *cpsR* and *cps16F* was downregulated (*p* < 0.05). As shown in **Figure 5**, the CP content, in comparison with the control, was significantly higher (*p* < 0.05) after growth with 1/2 MIC and 1/4 MIC of azithromycin. However, the CP content was not significantly affected following growth in the presence of 1/8 MIC of azithromycin (*p* > 0.05).

DISCUSSION

In the present study, the relationship between biofilm formation of *S. suis* and azithromycin have been investigated carefully. Some researchers have reported that subinhibitory concentrations of antimicrobial agents (such as moxifloxacin and triclosan) can either decrease (Pompilio et al., 2010) or increase (Bedran

<figure><img src="image_2.png" /></figure>

<figure><img src="image_3.png" /></figure>
et al., 2014) biofilm formation of bacterial pathogens. In the present study, we found that subinhibitory concentrations of azithromycin significantly decreased biofilm formation of S. suis. This finding is consistent with the previous publication (Starner et al., 2008; Gui et al., 2014).

Cell surface proteins and outer membrane proteins play a crucial role in biofilm formation of bacterial pathogens. Biofilm formation of bacterial pathogens mainly included three aspects: (i) bacterial pathogens adhere to surfaces, (ii) aggregation of micro-colonies of bacterial pathogens, and (iii) further expansion of the microbial community. Key stage of biofilm formation of bacterial pathogens is adhesion to surfaces. Cell surface proteins and outer membrane proteins may mediate cell attachment to surfaces.

When bacterial cells and a surface are close to each other, the biophysical interaction between a surface and bacterial cells plays an important role in adhesion. Therefore, cell surface proteins and outer membrane proteins play an important role in biofilm formation of bacterial pathogens. Membrane proteins such as OmpA mediate cell adhesion in *Acinetobacter baumannii* (Dallo et al., 2010). In the present

study, the expression of ABC superfamily ATP binding cassette transporter (G7SD52), CpsR (K0FG35), Cps1/2H (G8DTL7), CPS16F (E9NQ13), putative uncharacterized protein (G7SER0), NADP-dependent glyceraldehyde-3-phosphate dehydrogenase (G5L259), putative uncharacterized protein (G7S2D6), amino acid permease (B0M0G6), and NsuB (G5L351) changed; these proteins belong to membrane proteins and cell-surface proteins and might be involved in some molecular functions including transporter activity, nucleotide binding, motor activity, protein binding and catalytic activity (Supplementary Table S1). We predicted that these membrane proteins might affect the bacterial cell-cell interaction. Thus, membrane proteins might play a significant role in biofilm formation.

Interestingly, ABC superfamily ATP-binding cassette transporter (G7SD52) and NsuB (G5L351) was up-regulated in sub-MIC of azithromycin (in this study) and erythromycin-treated *S. suis* (Zhao et al., 2015). However, molecular function and biological process of NsuB (G5L351) are currently unknown. In future, NsuB (G5L351) should be studied. CpsR (K0FG35) and CPS16F (E9NQ13) was down-regulated in sub-MIC of azithromycin (in this study) and erythromycin-treated

A

<figure><img src="image_4.png" /></figure>

B

<figure><img src="image_5.png" /></figure>

C

<figure><img src="image_6.png" /></figure>

D

<figure><img src="image_7.png" /></figure>

FIGURE 3 | Scanning electron micrographs of S. suis ATCC700794 biofilm following growth in THB supplemented without azithromycin [(A or C), control], or with 1/2 MIC of azithromycin (B or D). Controls refer to the absence of azithromycin.
<table><caption>TABLE 2 | ITRAQ Identification of differentially expressed proteins.</caption><thead><tr><th>Accession</th><th>Proteins</th><th>Fold change<sup>a</sup></th></tr></thead><tbody><tr><td colspan="3"><strong>Up-regulated proteins</strong></td></tr><tr><td>G5L351</td><td>NsuB</td><td>7.12934739263001</td></tr><tr><td>G5KZF5</td><td>Putative uncharacterized protein</td><td>3.01653085375799</td></tr><tr><td>G8DTL7</td><td>Cps1/2H</td><td>2.02407561418484</td></tr><tr><td>G7SFA8</td><td>Transcriptional regulator, Cro/CI family</td><td>2.57596261219689</td></tr><tr><td>G7S2D6</td><td>Putative uncharacterized protein</td><td>3.00076898311981</td></tr><tr><td>Q9EZW2</td><td>Elongation factor Tu (Fragment)</td><td>3.9674279008791</td></tr><tr><td>G7S4L6</td><td>Putative uncharacterized protein</td><td>2.31735729535592</td></tr><tr><td>B0M0G6</td><td>Amino acid permease (Fragment)</td><td>2.16331972961307</td></tr><tr><td>A4W361</td><td>Uridine kinase</td><td>7.48970780907174</td></tr><tr><td>R4NZ92</td><td>TPR repeat-containing protein</td><td>2.70348016201752</td></tr><tr><td>G7SD52</td><td>ABC superfamily ATP binding cassette transporter, membrane protein</td><td>5.6411425449412</td></tr><tr><td>G7S7A9</td><td>FAD-dependent pyridine nucleotide-disulfide oxidoreductase</td><td>2.96465802924635</td></tr><tr><td colspan="3"><strong>Down-regulated proteins</strong></td></tr><tr><td>G7SER0</td><td>Putative uncharacterized protein</td><td>0.206326492539119</td></tr><tr><td>G7SHZ3</td><td>Bacteriophage protein, putative</td><td>0.480729105006118</td></tr><tr><td>K0FG35</td><td>CpsR</td><td>0.369579660174813</td></tr><tr><td>G5L259</td><td>NADP-dependent glyceraldehyde-3-phosphate dehydrogenase, putative</td><td>0.374165986672724</td></tr><tr><td>G7RZ18</td><td>Sortase-like protein</td><td>0.368308683014746</td></tr><tr><td>E9NQ13</td><td>CPS16F</td><td>0.24025009068188</td></tr><tr><td>G7SPA1</td><td>Putative scaffolding protein</td><td>0.324624727229277</td></tr></tbody></table>

<figure><img src="image_8.png" /></figure>

<figure><img src="image_9.png" /></figure>

S. suis (Zhao et al., 2015). Especially, in the present study, azithromycin also affected the expression of the other proteins, for example, Putative uncharacterized protein (G7SER0), NADP-dependent glyceraldehyde-3-phosphate dehydrogenase (G5L259), putative uncharacterized protein (G7S2D6), and amino acid permease (B0M0G6). This finding is not consistent with the previous results of our laboratory showing that subinhibitory concentrations of erythromycin inhibit biofilm

formation of S. suis (Zhao et al., 2015). It is generally known that azithromycin is the same class antibiotics as erythromycin, belonging to macrolide. However, erythromycin did not affect the expression of the four proteins (Zhao et al., 2015). In future, this finding should be studied carefully.

ABC transporters are common proteins in bacteria. They often transport a variety of substrates (for example polypeptides,

<footnote><sup>a</sup>1/2 MIC azithromycin treated vs. non-treated cells.</footnote>
ions and nutrients) (Lin et al., 2014). ABC transporters are also
presumably involved in the export of the competence-stimulating
peptide (autoinducers), which in turn regulate expression of
specific target genes (Li et al., 2002). Moreover, previous studies
have also demonstrated that ABC transporters are important as
they regulate biofilm formation (Selvaraj et al., 2014). Shannon
et al. have reported that ABC transporters are required for biofilm
formation by Pseudomonas fluorescens WCS365 (Hinsa et al.,
2003). Our laboratory recently reported that ABC superfamily
ATP-binding cassette transporter (G7SD52) was up-regulated in
sub-MIC of erythromycin or sub-MIC of tylosin-treated S. suis
(Zhao et al., 2015; Wang et al., 2016). In the present study, ABC
superfamily ATP-binding cassette transporter (G7SD52) was
upregulated in sub-MIC of azithromycin-treated cell (treated vs.
untreated). However, azithromycin did not affect the expression
of histidine kinase of the competence regulon (comD; G5L3D2)
and response regulator (comE; G7S4A2) in the present study.
Interestingly, erythromycin affects the expression of the two
proteins (Zhao et al., 2015). Li et al. (2002) have also found
that comD and comE are implicated in biofilm formation of
S. mutans. So far, the detailed molecular mechanism was still
unknown.

Some researchers have reported that the *S. suis* mutant impaired in capsule expression acquire a biofilm-positive phenotype in the previous publication (Tanabe et al., 2010). Bonifait et al. have reported that a hydrophilic capsule hinder hydrophobic components or structures. Moreover, Bonifait et al. (2010) have also found that the hydrophobic components or structures play an important role in biofilm formation of *S. suis*. Non-encapsulated *S. suis* strains may form thick biofilms (Benga et al., 2004). Specifically, in other species, Qin et al. (2013) have reported that reduced *S. pneumoniae* CP may increase biofilm development. Joseph et al. reported that *Vibrio vulnificus* CP expression actually inhibited biofilm formation (Joseph and Wright, 2004). Lakkitjaroen et al. (2014) have reported that the inactivation of Cps2F (glycosyltransferases) often caused capsule loss in *S. suis*. Cps2F and Cps2H may be involved in the biosynthesis of serotype 2 CP. In this study, azithromycin affected the biosynthesis of the CPS enzymes, for example, CpsR (K0FG35), Cps1/2H (G8DTL7), and CPS16F (E9NQ13). This finding is consistent with the previous results of our laboratory showing that sub-MIC erythromycin inhibits biofilm formation of *S. suis* (Zhao et al., 2015). However, Cps1/2H (G8DTL7) was downregulated (fold change: 0.30) in sub-MIC of erythromycin-treated *S. suis* (Zhao et al., 2015). Interestingly, Cps1/2H (G8DTL7) was up-regulated (fold change: 2.024) in sub-MIC of azithromycin-treated *S. suis* (in this study). It is common knowledge that azithromycin is derived from erythromycin, belonging to macrolide. We speculated that azithromycin had different molecule structure in comparison with erythromycin, which in turn might generate the different proteome patterns. However, the detailed molecular mechanism was still unknown. In future, this finding should be studied carefully. In brief, we speculated that azithromycin might affect the biosynthesis of the CP.

Recently, Lee et al. have investigated the role of CP in biofilm
formation in *V. vulnificus*. *V. vulnificus* mutant impaired in

CP expression increases cell aggregation, adherence to abiotic surfaces, and hydrophobicity of the cell surface. In comparison with wild type, *V. vulnificus* mutant forms significantly more biofilm. Furthermore, addition of CP decrease biofilms formation of a CP-deficient mutant. After the CP-producing wild type is degraded endogenous CP with an enzyme, the CP-producing wild type increases biofilm formation (Lee et al., 2013). In the present study, the CP content, in comparison with the control, was significantly higher after growth with 1/2 MIC of azithromycin and 1/4 MIC of azithromycin. Houde et al. have reported that *S. suis* mutants impaired in capsule expression are easily killed by immune cells. Therefore, CP of *S. suis* is a significant virulence factor of the bacteria. Furthermore, CP is also involved in adhesion of the bacteria (Houde et al., 2012). Key stage of biofilm formation of bacterial pathogens is adhesion to surfaces. We speculated that azithromycin might affect adhesion of *S. suis* by increasing capsular polysaccharide content. In brief, further examination of the relationship of capsule structure to biofilms should be studied.

In short, subinhibitory concentrations of azithromycin might
decrease biofilm formation of S. suis in the present study.
At two different conditions (1/2 MIC of azithromycin non-
treated cells and treated cells), we carried out comparative
proteomic analyses of cells by using iTRAQ technology. In
the present study, 19 differentially expressed proteins were
identified, 12 (63.2%) of which displayed increased and 7
(36.8%) displayed decreased abundance. Several cell surface
proteins [such as ABC superfamily ATP-binding cassette
transporter (G7SD52), CpsR (K0FG35), Cps1/2H (G8DTL7),
CPS16F (E9NQ13), putative uncharacterized protein (G7SER0),
NADP-dependent glyceraldehyde-3-phosphate dehydrogenase
(G5L259), putative uncharacterized protein (G7S2D6), Amino
acid permease (B0M0G6), and NsuB (G5L351)] were found to
be implicated in biofilm formation. It is common knowledge
that azithromycin is derived from erythromycin, belonging
to macrolide. We speculated that azithromycin had different
molecule structure in comparison with erythromycin, which in
turn might generate the different proteome patterns. We also
discovered that azithromycin might affect the biosynthesis of the
CP. These data showed a useful starting point for more focused
studies to understand what exactly was going on. However, the
detailed mechanism was still unknown. In future, the relationship
between capsule structure and biofilms of S. suis should be
studied to delineate the complex mechanism.

AUTHOR CONTRIBUTIONS

Y-BY designed the whole experiment. Y-HI directed the completion of the experiment. J-QC, Y-LZ, J-WB, W-YD, Y-HZ, X-YC, and DL provided help during the experiment.

FUNDING

This work was supported by the National Natural Science
Foundation of China (No. 31472231).
# ACKNOWLEDGMENT

Thank to Shanghai Applied Protein Technology Co. Ltd for the help of iTRAQ, sequence database searching and data analysis.

# REFERENCES

Bedran, T. B. L., Grignon, L., Spolidorio, D. P., and Grenier, D. (2014). Subinhibitory concentrations of triclosan promote *Streptococcus mutans* biofilm formation and adherence to oral epithelial cells. *PLoS ONE* 9:e89059. doi: 10.1371/journal.pone.0089059

Benga, L., Goethe, R., Rohde, M., and Valentin-Weigand, P. (2004). Non-encapsulated strains reveal novel insights in invasion and survival of *Streptococcus suis* in epithelial cells. *Cell. Microbiol.* 6, 867–881. doi: 10.1111/j.1462-5822.2004.00409.x

Bojarska, A., Molska, E., Janas, K., Skoczynska, A., Stefaniuk, E., Hryniewicz, W., et al. (2016). *Streptococcus suis* in invasive human infections in Poland: clonality and determinants of virulence and antimicrobial resistance. *Eur. J. Clin. Microbiol. Infect. Dis.* 35, 917–925. doi: 10.1007/s10096-016-2616-x

Bonifait, L., Gottschalk, M., and Grenier, D. (2010). Cell surface characteristics of nontypeable isolates of *Streptococcus suis*. *FEMS Microbiol. Lett.* 311, 160–166. doi: 10.1111/j.1574-6968.2010.02086.x

Cuesta, G., Suarez, N., Bessio, M. I., Ferreira, F., and Massaldi, H. (2003). Quantitative determination of pneumococcal capsular polysaccharide serotype 14 using a modification of phenol-sulfuric acid method. *J. Microbiol. Methods* 52, 69–73. doi: 10.1016/s0167-7012(02)00151-3

Dallo, S. F., Denno, J., Hong, S., and Weitao, T. (2010). Adhesion of *Acinetobacter baumannii* to extracellular proteins detected by a live cell-protein binding assay. *Ethn. Dis.* 20, 7–11.

Espinosa, I., Baez, M., Lobo, E., Martinez, S., and Gottschalk, M. (2016). Antimicrobial activity of penicillin G and N-acetylcystein on planktonic and sessile cells of *Streptococcus suis*. *Pol. J. Microbiol.* 65, 105–109. doi: 10.5604/17331331.1197282

Gui, Z. H., Wang, H. F., Ding, T., Zhu, W., Zhuang, X. Y., and Chu, W. H. (2014). Azithromycin reduces the production of alpha-hemolysin and biofilm formation in *Staphylococcus aureus*. *Indian J. Microbiol.* 54, 114–117. doi: 10.1007/s12088-013-0438-4

Hinsa, S. M., Espinosa-Urgel, M., Ramos, J. L., and O'Toole, G. A. (2003). Transition from reversible to irreversible attachment during biofilm formation by *Pseudomonas fluorescens* WCS365 requires an ABC transporter and a large secreted protein. *Mol. Microbiol.* 49, 905–918. doi: 10.1046/j.1365-2958.2003.03615.x

Houde, M., Gottschalk, M., Gagnon, F., Van Calsteren, M. R., and Segura, M. (2012). *Streptococcus suis* capsular polysaccharide inhibits phagocytosis through destabilization of lipid microdomains and prevents lactosylceramide-dependent recognition. *Infect. Immun.* 80, 506–517. doi: 10.1128/iai.05734-11

Joseph, L. A., and Wright, A. C. (2004). Expression of *Vibrio vulnificus* capsular polysaccharide inhibits biofilm formation. *J. Bacteriol.* 186, 889–893. doi: 10.1128/jb.186.3.889-893.2004

Lakkitjaroen, N., Takamatsu, D., Okura, M., Sato, M., Osaki, M., and Sekizaki, T. (2014). Capsule loss or death: the position of mutations among capsule genes sways the destiny of *Streptococcus suis*. *FEMS Microbiol. Lett.* 354, 46–54. doi: 10.1111/1574-6968.12428

Lee, K. J., Kim, J. A., Hwang, W., Park, S. J., and Lee, K. H. (2013). Role of capsular polysaccharide (CPS) in biofilm formation and regulation of CPS production by quorum-sensing in *Vibrio vulnificus*. *Mol. Microbiol.* 90, 841–857. doi: 10.1111/mmi.12401

Li, Y.-H., Tang, N., Aspiras, M. B., Lau, P. C. Y., Lee, J. H., Ellen, R. P., et al. (2002). A quorum-sensing signaling system essential for genetic competence in *Streptococcus mutans* is involved in biofilm formation. *J. Bacteriol.* 184, 2699–2708. doi: 10.1128/jb.184.10.2699-2708.2002

Lin, C. H., Su, S. C., Ho, K. H., Hsu, Y. W., and Lee, K. R. (2014). Bactericidal effect of sulbactam against *Acinetobacter baumannii* ATCC 19606 studied by 2D-DIGE and mass spectrometry. *Int. J. Antimicrob. Agents* 44, 38–46. doi: 10.1016/j.ijantimicag.2014.03.004

# SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: http://journal.frontiersin.org/article/10.3389/fmicb.2016.01659

Nakamura, Y., Yamamoto, N., Kino, Y., Yamamoto, N., Kamei, S., Mori, H., et al. (2016). Establishment of a multi-species biofilm model and metatranscriptomic analysis of biofilm and planktonic cell communities. *Appl. Microbiol. Biotechnol.* 100, 7263–7279. doi: 10.1007/s00253-016-7532-6

Pompilio, A., Catavitello, C., Picciani, C., Confalone, P., Piccolomini, R., Savini, V., et al. (2010). Subinhibitory concentrations of moxifloxacin decrease adhesion and biofilm formation of *Stenotrophomonas maltophilia* from cystic fibrosis. *J. Med. Microbiol.* 59, 76–81. doi: 10.1099/jmm.0.011981-0

Qin, L., Kida, Y., Imamura, Y., Kuwano, K., and Watanabe, H. (2013). Impaired capsular polysaccharide is relevant to enhanced biofilm formation and lower virulence in *Streptococcus pneumoniae*. *J. Infect. Chemother.* 19, 261–271. doi: 10.1007/s10156-012-0495-3

Selvaraj, A., Sumantran, V., Chowdhary, N., and Kumar, G. R. (2014). Prediction and classification of ABC transporters in *Geobacter sulfurreducens* PCA using computational approaches. *Curr. Bioinform.* 9, 166–172. doi: 10.2174/1574893608999140109113236

Smith, H. E., Damman, M., van der Velde, J., Wagenaar, F., Wisselink, H. J., Stockhofe-Zurwieden, N., et al. (1999). Identification and characterization of the cps locus of *Streptococcus suis* serotype 2: the capsule protects against phagocytosis and is an important virulence factor. *Infect. Immun.* 67, 1750–1756.

Starner, T. D., Shrout, J. D., Parsek, M. R., Appelbaum, P. C., and Kim, G. (2008). Subinhibitory concentrations of azithromycin decrease nontypeable *Haemophilus influenzae* biofilm formation and diminish established biofilms. *Antimicrob. Agents Chemother.* 52, 137–145. doi: 10.1128/aac.00607-07

Tanabe, S. I., Bonifait, L., Fittipaldi, N., Grignon, L., Gottschalk, M., and Grenier, D. (2010). Pleiotropic effects of polysaccharide capsule loss on selected biological properties of *Streptococcus suis*. *Can. J. Vet. Res.* 74, 65–70.

Wang, S., Yang, Y. B., Zhao, Y. L., Zhao, H. H., Bai, J. W., Chen, J. Q., et al. (2016). Sub-MIC tylosin inhibits *Streptococcus suis* biofilm formation and results in differential protein expression. *Front. Microbiol.* 7:384. doi: 10.3389/fmicb.2016.00384

Wang, Y., Yi, L., Wang, S. H., Fan, H. J., Ding, C., Mao, X., et al. (2015). Crystal structure and identification of two key amino acids involved in AI-2 production and biofilm formation in *Streptococcus suis* LuxS. *PLoS ONE* 10:e0138826. doi: 10.1371/journal.pone.0138826

Yang, Y. B., Wang, S., Wang, C., Huang, Q. Y., Bai, J. W., Chen, J. Q., et al. (2015). Emodin affects biofilm formation and expression of virulence factors in *Streptococcus suis* ATCC700794. *Arch. Microbiol.* 197, 1173–1180. doi: 10.1007/s00203-015-1158-4

Yufang, Y., Linlin, L., Xuenan, S. U. N., Shuxue, S. U. N., and Zhaolin, D. (2006). The isolation and purification of the capsular polysaccharide from group B streptococcus. *Chin. J. Biochem. Pharm.* 27, 166–169.

Zhao, Y. L., Zhou, Y. H., Chen, J. Q., Huang, Q. Y., Han, Q., Liu, B., et al. (2015). Quantitative proteomic analysis of sub-MIC erythromycin inhibiting biofilm formation of S-suis in vitro. *J. Proteom.* 116, 1–14. doi: 10.1016/j.jprot.2014.12.019

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2016 Yang, Chen, Zhao, Bai, Ding, Zhou, Chen, Liu and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.